Form 4 for ABT Abbott Laboratories
Accepted 2023-02-22 00:00:00 ET · period of report 2023-02-17 · accession 0001415889-23-003046 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-22 | 2023-02-17 | ABT | Boudreau Philip P | VP | A - Grant | $0.00 | +4,855 | 24.9K | +24% | $0 |
| D | 2023-02-22 | 2023-02-17 | ABT | Boudreau Philip P | VP | A - Grant | $0.00 | +19.1K | 19.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common shares without par value | 2023-02-17 | A | A | 4,855 | $0.00 | 24,924 | D | — | — | (F1) These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. |
| 2 | Derivative | Option (right to buy) | 2023-02-17 | A | A | 19,149 | $0.00 | 19,149 | D | $106.24 · 2024-02-17 to 2033-02-16 | 19,149 Common Shares | (F3) Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,383 on February 17, 2024, 6,383 on February 17, 2025, and 6,383 on February 17, 2026. |